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Abstract
Background: Serological tests to detect antibodies specific to Plasmodium vivax could be a valuable
tool for epidemiological studies, for screening blood donors in areas where the malaria is not
endemic and for diagnosis of infected individuals. Because P. vivax cannot be easily obtained in vitro,
ELISA assays using total or semi-purified antigens are rarely used. Based on this limitation, we
tested whether recombinant proteins representing the 19 kDa C-terminal region of the merozoite
surface protein-1 of P. vivax (MSP119) could be useful for serological detection of malaria infection.
Methods: Three purified recombinant proteins produced in Escherichia coli (GST-MSP119, His6-
MSP119 and His6-MSP119-PADRE) and one in Pichia pastoris (yMSP119-PADRE) were compared for
their ability to bind to IgG antibodies of individuals with patent P. vivax infection. The method was
tested with 200 serum samples collected from individuals living in the north of Brazil in areas
endemic for malaria, 53 serum samples from individuals exposed to Plasmodium falciparum infection
and 177 serum samples from individuals never exposed to malaria.
Results: Overall, the sensitivity of the ELISA assessed with sera from naturally infected individuals
was 95%. The proportion of serum samples that reacted with recombinant proteins GST-MSP119,
His6-MSP119, His6-MSP119-PADRE and yMSP119-PADRE was 90%, 93.5%, 93.5% and 93.5%,
respectively. The specificity values of the ELISA determined with sera from healthy individuals and
from individuals with other infectious diseases were 98.3% (GST-MSP119), 97.7% (His6-MSP119 and
His6-MSP119-PADRE) or 100% (yMSP119-PADRE).
Conclusions:  Our study demonstrated that for the Brazilian population, an ELISA using a
recombinant protein of the MSP119 can be used as the basis for the development of a valuable
serological assay for the detection of P. vivax malaria.
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Background
Plasmodium vivax accounts worldwide for an estimated
70–80 million cases of malaria per year [1]. In some coun-
tries such as Brazil, P. vivax was responsible for approxi-
mately 79% of the 389,736 cases of the disease reported
in 2001 [2].
Laboratory methods are important tools for the control of
the disease progress. They can be useful for the individual
diagnosis or for the patients' follow-up after specific anti-
malaria treatment. Conventional light microscopy has
been widely used for malaria diagnosis. However, outside
areas where malaria is endemic, it is rarely performed.
Also, this method is time consuming and requires trained
personnel.
In attempts to overcome these problems several rapid
diagnostic tests have been developed recently. These tests
detect specific proteins such as HRP2, a histidine rich pro-
tein 2, or pLDH, lactate dehydrogenase, in unfractionated
blood of patients with malaria. However, these assay do
not differentiate P. vivax from Plasmodium malariae or Plas-
modium ovale infections, and vary in their sensitivity and
specificity (reviewed in reference [3]).
Molecular diagnosis by PCR is described as the most sen-
sitive and specific method for Plasmodium  detection.
Genus- and species-specific primers have been used to
amplify  Plasmodium  ssrRNA genes of the four human
malaria parasites and to detect mixed infections [4-6].
However, this methodology is costly and requires trained
personnel for its implementation.
Detection of antibodies by immunofluorescence or ELISA
has been used for seroepidemiology of malaria. However,
in the case of P. vivax, the difficulty of blood stage cultiva-
tion has been hindering the use of these methodologies.
Production of recombinant proteins through the tech-
niques of genetic engineering may provide sufficient P.
vivax blood stage antigen(s) for the establishment of spe-
cific serological assays.
In the course of immuno-epidemiological studies using
recombinant proteins based on the sequence of the Mero-
zoite Surface protein-1 (MSP1) of P. vivax, we found that
a recombinant protein representing the 19 kDa region of
MSP1 (MSP119) was highly immunogenic during natural
infection in humans [7,8]. This recombinant protein was
recognized by antibodies of a large fraction of Brazilian
individuals recently exposed to P. vivax [7]. This observa-
tion was subsequently confirmed in studies performed in
Korea, where more than 90% of P. vivax-infected individ-
uals displayed specific antibodies to P. vivax MSP119 [9].
Also important was the observation that the P. vivax
MSP119 gene displays very limited allele polymorphism in
different regions of the world that does not restrict recog-
nition by human antibodies [10,11]. Together, these
results suggested that it could be possible to develop an
ELISA using a single recombinant protein based on the P.
vivax MSP119. This relatively simple and inexpensive tech-
nique could be of great applicability for epidemiological
studies, the screening of blood donors and the serological
diagnosis of malaria caused by P. vivax.
In the present study three purified recombinant proteins
produced in E. coli (GST-MSP119, His6-MSP119 and His6-
MSP119-PADRE) and one in Pichia pastoris (yMSP119-
PADRE) were compared for their ability to be recognized
by IgG antibodies of individuals with patent P. vivax infec-
tion. Serological evaluation was performed with serum
samples collected from individuals living in areas
endemic for malaria in the north of Brazil and compared
to serum samples from individuals never exposed to P.
vivax malaria.
Materials and methods
Study population
Sera from 430 individuals were used in this study, of
which 200 were from patients with patent P. vivax malaria
and 230 from persons not exposed to P. vivax malaria
(negative controls). The blood samples from P. vivax
patients were collected in the state of Pará, in the north of
Brazil, in areas endemic for malaria: 103 from Belém, 21
from Marabá, 20 from Itaituba, 20 from Tailândia, 36
from Igarapé-Açu. Patent infection was documented by
microscopic analysis of Giemsa-stained blood drops.
These samples were obtained between January 1996 and
July 1999 with informed consent of all individuals and
kept at -20°C.
The 230 individuals non-exposed to P. vivax malaria
included: (i) 49 donors to blood banks in the city of São
Paulo, an area where malaria is not endemic (negative
controls); (ii) 108 blood bank donors with unrelated
infectious diseases, detected serologically; among them
21 with Chagas Disease, 21 with syphilis, 19 with HBV, 21
with HCV, 14 with HTLV and 12 with HIV; (iii) 10 indi-
viduals positive for antinuclear antibodies (ANA) and 10
for rheumatoid factors (RF); (iv) 53 individuals living in
distinct areas in West Africa where malaria caused by Plas-
modium falciparum is endemic: a) 26 adults without clear
symptoms of malaria or other infectious disease from Sen-
egal (n = 19) and Gambia (n = 7), b) seven children from
Gambia during patent infection by P. falciparum, c) 20
malaria immune adults from Ghana. Aliquots of these
samples were kindly supplied by Dr. Marcelo Urbano Fer-
reira (Universidade de São Paulo, São Paulo) and Dr. Sil-
via Di Santi (Superitendência de Controle de Endemias,
SUCEN, São Paulo). Clinical and laboratory data were
reported elsewhere [12-14].Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/39
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Recombinant proteins
The recombinant proteins used in the present study repre-
sent amino acids 1616–1704 of the MSP-1 (Belem strain)
of P. vivax. These proteins were expressed in E. coli (GST-
MSP119, His6-MSP119 and His6-MSP119-PADRE, ref. 15)
or Pichia pastoris (yMSP119-PADRE, ref. 16). The genera-
tion of the plasmids and expression/purification of the
recombinant proteins produced in E. coli or Pichia pas-
toris were performed as described in references 15 and 16,
respectively.
ELISA for detection of human antibodies
Human IgG antibodies against MSP119 were detected by
ELISA as described [7]. ELISA plates were coated with 200
ng/well of each recombinant protein. The amount of
recombinant protein gave the same OD492 when we used
an anti-MSP119 MAb [17]. Fifty µl of each solution were
added to each of 96 well plates (High binding, Costar).
After overnight incubation at room temperature (rt), the
plates were washed with PBS-Tween (0.05%, v/v) and
blocked with PBS-milk (5% w/v) for two hours at 37°C.
Serum samples were diluted 1:100 in this same solution
and 50 µl of each sample was added to each well in dupli-
cate. After incubation for two hours at rt and washes with
PBS-Tween, 50 µl a solution containing peroxidase-conju-
gated goat anti-human IgG (Fc specific) diluted 1:10,000
(Sigma) were added to each well. The enzymatic reaction
was developed by the addition of 1 mg/ml of o-phenylen-
ediamine (Sigma) diluted in phosphate-citrate buffer, pH
5.0, containing 0.03% (v/v) hydrogen peroxide, and was
stopped by the addition of 50 µl of 4 N H2SO4. Plates were
read at 492 nm (OD492) with an ELISA reader (SLT SPEC-
TRA, SLT Labinstruments, Austria). The individual values
of OD492  obtained for the recombinant proteins of
MSP119 were corrected by subtraction of the individual
values of OD492 obtained against glutathione S-transferase
(GST).
Statistical analysis
OD492 from different samples were plotted using compu-
ter graphics software (GraphPad Prism, Version 3.0, San
Diego, California). Cutoff values of each recombinant
protein in ELISA were calculated as the mean OD492 of
sera from 49 blood donors plus five standard deviations
(SD). The values for sensitivity and specificity were esti-
mated as described [18] with microscopy used as the gold
standard. The Kruskal-Wallis test was used to test the sig-
nificance of differences between the group values. Differ-
ences between proportions were analyzed by a Chi-square
test.
Results
Reactivity of recombinant proteins expressed in distinct 
vectors with serum samples from individuals with patent P. 
vivax
Four recombinant proteins obtained as earlier described
in references 15 and 16 (Table 1) were used. SDS-PAGE
analysis of each recombinant protein revealed a single
band of the expected molecular weight after Coomassie
blue [15,16] or Silver staining (data not shown).
An IgG survey of the serum samples of individuals with
patent P. vivax infection patients showed that the values of
positivity were quite similar with the four recombinant
antigens employed. Ninety to 93.5% of the 200 serum
samples tested were positive for IgG with the recombinant
proteins based on the MSP119.
When we compared the OD492 values from serum samples
of P. vivax infected individuals, we observed that values
obtained for the recombinant proteins His6-MSP119 and
His6-MSP119-PADRE were significantly higher than those
obtained for GST-MSP119 (Fig. 1, P < 0.01, Kruskal-Wallis
test). On the other hand, no statistically significant differ-
ence was observed among values obtained by the compar-
ison of the recombinant proteins His6-MSP119, His6-
MSP119-PADRE and yMSP119-PADRE, or GST-MSP119
and yMSP119-PADRE (P > 0.05, Kruskal-Wallis test).
Sera from the few individuals who tested negative towards
all four recombinant proteins were also tested for the rec-
ognition of recombinant proteins representing the N-ter-
minal region of P. vivax MSP1, MSP3α (C-terminal) or
MSP3β(N and C-terminal and entire protein, references
19 and 20). All of them failed to recognize any of the
recombinant protein tested (data not shown). However,
Table 1: Recombinant proteins based on the MSP119 of P. vivax.
Recombinant protein Vector Microorganism Molecular Weight (kDa) Ref.
GST-MSP119 pGEX-3X E. coli 36 15
His6-MSP119 pET-14b E. coli 18 15
His6-MSP119-PADRE* pET-14b E. coli 18 15
yMSP119-PADRE* pPIC-9K Pichia pastoris 18 16
* PADRE epitope is composed of amino acids AKFVAAWTLKAAA.Malaria Journal 2003, 2 http://www.malariajournal.com/content/2/1/39
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we detected antibodies IgM anti-MSP119 in 90% (9/10) of
these IgG negative individuals. If we consider the results
of detection of antibodies IgG and IgM for MSP119, the
sensitivity of the assay was of 99.5%. These 10 individuals
were primo-infected and therefore the presence of IgM but
not IgG may reflect a delay in the immunoglobulin class
switch.
From the 200 individuals that we evaluated, 111 were
primo-infected. One hundred and one of them had spe-
cific IgG for the recombinant proteins that we tested. Only
10 were negative for IgG and, as mentioned above, 9 of
them had specific IgM.
Evaluation of the specificity of the recombinant proteins 
tested with serum samples from individuals exposed to P. 
falciparum, from unrelated diseases, or healthy donors
The specificity of the assay using recombinant P. vivax
antigens was examined with 230 serum samples from
individuals without previous history of P. vivax malaria,
including individuals exposed to P. falciparum malaria,
individuals with unrelated diseases or healthy individu-
als. Due to limitations on the volume of each sample
available, sera from African individuals exposed to P. fal-
ciparum  were tested only against recombinant protein
His6-MSP119. For the calculation of the specificity of the
assay using the recombinant protein His6-MSP119  the
results that was obtained did not include sera from Afri-
can individuals. The specificity values determined with
sera from healthy individuals and sera from individuals
with other infectious diseases, were 98.3% (GST-MSP119),
97.7% (His6-MSP119and His6-MSP119-PADRE) and 100%
(yMSP119-PADRE). In figure 2, we compared the OD492
values from serum samples of P. vivax infected individu-
als, individuals exposed to P. falciparum and individuals
with unrelated diseases.
Discussion
Due to the difficulties in cultivating blood stages of P.
vivax, serological diagnosis of patent P. vivax malaria can
best be accomplished with the use of recombinant pro-
teins. In the present study, we compared for purified
Distribution of OD492 data for 200 sera from individuals with patent malaria infection caused by P.vivax Figure 1
Distribution of OD492 data for 200 sera from individuals with patent malaria infection caused by P. vivax. The symbols represent 
the reactivity of each serum sample tested in duplicate at 1:100 dilution against the indicated recombinant proteins. The hori-
zontal line inside the drops for each recombinant protein represents the cut-off values (0.127, 0.170, 0.198 and 0.500 for GST-
MSP119, His6-MSP119, His6-MSP119-PADRE and yMSP119-PADRE, respectively).
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recombinant proteins produced in E. coli or in Pichia pas-
toris in their ability to be recognized by IgG antibodies of
Brazilian individuals with patent P. vivax infection. Our
study demonstrated that, for the Brazilian population, an
ELISA using a single recombinant protein based on the P.
vivax MSP119 kDa can serve as the basis for the develop-
ment of a sensitive serological test that can be used for epi-
demiological studies, screening blood donors and
diagnosis of P. vivax malaria.
So far, we do not have an estimate of the timing required
after mosquito bite for the appearance of specific antibod-
ies. To be accurate, this information should be obtained
during experimental infection in primates. Nevertheless,
we were able to determine that from the 111 primo-
infected individuals that we evaluated, 101 (90.9%) had
specific IgG to MSP119. This information is important and
suggests that IgG antibodies specific for MSP119 are suita-
ble for testing individuals who are traveling or have
traveled for the first time through malaria endemic areas.
On the other hand, the persistence of the IgG antibodies
specific for MSP119 is still a matter that has to be further
evaluated. In previous studies we determined that the
antibody titers decreased relatively rapidly after treatment
[8]. However, studies are underway using these recently
generated recombinant proteins.
Distribution of the OD492 data for sera from individuals with patent P. vivax malaria, from individuals exposed to P. falciparum,  from individuals with unrelated diseases or healthy controls Figure 2
Distribution of the OD492 data for sera from individuals with patent P. vivax malaria, from individuals exposed to P. falciparum, 
from individuals with unrelated diseases or healthy controls. The symbols represent the reactivity of each serum sample tested 
in duplicate at 1:100 dilution against the indicated recombinant proteins. The abbreviations are as follow: A) Pv= individuals 
with P. vivax malaria (n = 200), B) Pf= individuals from areas where P. falciparum malaria is endemic (n = 53), C) Cha = individu-
als with Chagas Disease (n = 21), D) Syp = individuals with syphilis (n = 21), E) HBV = individuals with hepatitis B (n = 19), F) 
HCV= individuals with hepatitis C (n = 21), G) HTLV = individuals with HTLV (n = 14), H) HIV= individuals with HIV (n = 12), 
I) ANA = individuals positive for antinuclear antibodies (n = 10), J) RF = individuals positive for rheumatoid factors (n = 10), L) 
Healthy = Healthy individuals (n = 49). Sera from African individuals exposed to P. falciparum were tested only against recom-
binant protein His6-MSP119. The horizontal line inside the drops for each recombinant protein represents the cut-off values 
(0.127, 0.170, 0.198 and 0.500 for GST-MSP119, His6-MSP119, His6-MSP119-PADRE and yMSP119-PADRE, respectively).
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An important observation from our study was the fact that
sera from African individuals naturally exposed to P. falci-
parum failed to cross-react with the recombinant protein
His6-MSP119 (Figure 2). As a control, 39 of these sera were
also tested against a recombinant protein derived of the
MSP-2 of P. falciparum. The percentage of responders was
69.2% (data not shown). The lack of cross-reactivity may
have several implications and should be further evaluated
in the light of the current knowledge that both MSP119
share similarities in their predicted tertiary structures [21].
For epidemiological studies, for the screening of blood
donors and the serological diagnosis of P. vivax malaria,
the lack of cross reactivity can be a major advantage. Nev-
ertheless, the absence of cross-recognition of P. vivax
MSP119 by antibodies from P. falciparum-exposed individ-
uals has may also have immunological consequences at
the level of acquired immunity and vaccine development
in areas where both malarias are prevalent. Detailed stud-
ies will be required to determine whether sera from P.
vivax  infected individuals also fail to recognize recom-
binant proteins representing the P. falciparum MSP119.
Recently, a direct sandwich ELISA to detect antibodies
against the C-terminal region of MSP-1 was proposed as a
potential diagnostic method for Plasmodium vivax exposed
individuals from Korea [22]. This assay showed a high
sensitivity (99.5%) indicating that recombinant proteins
containing the C-terminal region of P. vivax MSP-1 may be
used in individuals from different parts of the world.
It is also important to mention that it is very likely that
serological detection of P. vivax malaria can be further
improved by several distinct strategies. We are currently
trying to improve the detection level by the combined use
of other recombinant proteins based on the sequence of
other blood stage antigens of P. vivax such as the Plasmo-
dium vivax Merozoite Surface Proteins-3α and β, Apical
Membrane Antigen-1 and the Duffy Binding Protein
[19,20,23,24]. Also, we are developing a chemilumines-
cent enzyme-linked immunosorbent assay that may
greatly improve the sensitivity, eliminating the few false
negative and false positive samples we had [25,26].
Finally, our results support the notion that recombinant
proteins based on the P. vivax MSP119 kDa can be useful
for the development of a rapid immunochromatographic
assay for field studies, small laboratories and blood banks
(reviewed in references 3 and 27).
Conclusions
Our study demonstrated that for the Brazilian population,
an ELISA using a single recombinant protein based on the
P. vivax MSP119 can serve as the basis for the development
of a valuable serological assay for the detection of P. vivax
malaria.
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